Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Larry Friedrich, PharmD

Spero Therapeutics

Disclosure(s): Spero Therapeutics: Employee

Poster(s):

2232 - Association between Inappropriate Empiric Therapy (IET) and 30-Day Emergency Department/Inpatient (ED/IP) Visits Among Adult Outpatients (OPs) with Complicated Urinary Tract Infections (cUTIs)
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
2233 - Clinical Risk Scores (CRSs) to Predict Resistance to Trimethoprim-Sulfamethoxazole (TMP-SMX), Fluoroquinolone (FQ), Nitrofurantoin (NIT), or Third Generation Cephalosporins (3GC) among Adult Outpatients (OPs) with Complicated Urinary Tract Infections (cUTIs)
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET